Figure 1.

Therapeutic treatment of subcutaneous B16-ovalbumin (B-16-OVA) melanoma with Methanobrevibacter smithii-OVA (MS-OVA). C57BL/6 mice were given 10⁶ B16-OVA melanoma tumor cells subcutaneously (s.c.) in the dorsal flank. On days 4, 8, and 18 after tumor injection, 20 μg MS-OVA was injected s.c. at the base of the tail away from the tumor site. (A): Tumor growth in individual mice is shown for vaccinated mice and non-vaccinated mice; (B): The mean frequency ± SD of OVA-CD8⁺ T cells is shown at two time points for vaccinated mice (n = 4/group). This was repeated twice.